Previous exploratory treatments have affirmed the promise of CAR-T therapy in autoimmune diseases; notably, Schett and his team have been pioneering in the use of CD19-targeted CAR-T therapy to mitigate refractory SLE and its complication lupus nephritis [15,16]. This evidence concerns the gene CD19 and autoimmune disease.